Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

INSULIN GLARGINE

All injection strengths: general benefit

Other products in the same Health Canada class (A10AE) — coverage varies; not interchangeable

  • Insulin degludec (Tresiba): general benefit
  • Insulin detemir (Levemir Penfill): general benefit

Basaglar · DIN 02461528 · 100U/mL · injection solution-KwikPen (80U) pre-filled pen 5x3mL Pk

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Basaglar · DIN 02461528 Manufacturer: Eli Lilly Canada Inc.; listing date 2019-03-28 Health Canada: Marketed since 2017-08-18 · brand BASAGLAR · ATC A10AE04 INSULIN GLARGINE · form Solution · route Subcutaneous · ingredients INSULIN GLARGINE 100 UNIT/ML · company Eli lilly canada inc · schedule Schedule d
Check this DIN again · Health Canada product record

Basaglar: Formulary list price $84.7000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $84.7000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94916 · Verify on the e-Formulary ↗ (DIN 02461528)

Source record
DIN 02461528: Basaglar Raw flags: insOH=Y, sec3=Y Item: 682014017; group id 782; item number 1905; lccId None; manufacturer id LIL Source form: Inj Sol-KwikPen (80U) Pref Pen 5x3mL Pk; strength: 100U/mL Recorded listing: General benefit; diabetes medication flag Source prices (unrounded): $84.7000; ministry $84.7000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461528 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94916
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:20:14 Insulins (Long Acting)) and how they are covered

Matched class: 68:20:14 Insulins (Long Acting)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: INSULIN DEGLUDEC, INSULIN DETEMIR 68:20:14 Insulins (Long Acting)

INSULIN DEGLUDEC

· 3 products · General benefit · strengths: 100U/mL, 200U/mL · Inj Sol-3X5mL Cart Pk, Inj Sol-Flextouch Pref Pen 3x3mL Pk, Inj Sol-Flextouch Pref Pen 5x3mL Pk

INSULIN DETEMIR

· 2 products · General benefit · strengths: 100U/mL · Inj Sol-5x3mL Pk, Inj Sol-Pref Disp Pen 5X3mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:14
Full class listing Related classes: 68:20:02 Oral Anti-Diabetic Agents, 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS LANTUS [insulin glargine injection (rDNA origin)] is a recombinant human insulin analog indicated for once-daily subcutaneous administration in the treatment of patients over 17 years of age with Type 1 or Type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. LANTUS is also indicated in the treatment of pediatric patients (˃6 years old) with Type 1 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia . 1.1 Pediatrics Pediatrics (>6 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of LANTUS in pediatric patients over 6 years of age with Type 1 diabetes mellitus has been established. Therefore, Health Canada has authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. In elderly patients with diabetes, the initial dosing, dose increments, and maintenance dosage should be conservative to avoid hypoglycemic reactions. https://pdf.hres.ca/dpd_pm/00063800.PDF PM date: December 1, 2021 Source product: LANTUS; DIN 02245689; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.